Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways

Hin-Fung Yuen, Ka Kui Chan, Claire Grills, James T. Murray, Angela Platt-Higgins, Osama Sharaf Eldin, Ken O'Byrne, Pasi Janne, Dean A. Fennell, Patrick G. Johnston, Philip S. Rudland, Mohamed El-Tanani

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Purpose: Cancer cells have been shown to be more susceptible to Ran knockdown than normal cells. We nowinvestigate whether Ran is a potential therapeutic target of cancers with frequently found mutations that lead to higher Ras/MEK/ERK [mitogen-activated protein/extracellular signal-regulated kinase (ERK; MEK)] and phosphoinositide 3-kinase (PI3K)/Akt/mTORC1 activities.
Original languageEnglish
Pages (from-to)380-391
Number of pages12
JournalClinical Cancer Research
Volume18
Issue number2
DOIs
Publication statusPublished - 15 Jan 2012

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways'. Together they form a unique fingerprint.

  • Cite this

    Yuen, H-F., Chan, K. K., Grills, C., Murray, J. T., Platt-Higgins, A., Eldin, O. S., O'Byrne, K., Janne, P., Fennell, D. A., Johnston, P. G., Rudland, P. S., & El-Tanani, M. (2012). Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways. Clinical Cancer Research, 18(2), 380-391. https://doi.org/10.1158/1078-0432.CCR-11-2035